Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Daniel Clark maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and raises the price target from $45 to $52.
Leerink Partners analyst Daniel Clark maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and raises the price target from $45 to $52.